Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982767 | 0.88 | SLC6A4 (0.46) | TACR1SLC6A4SLC6A9CACNA2D1CACNA1B | |
| SCHEMBL4636695 | 0.86 | NAAA (0.53) | TACR1CARM1PRMT6NAAACACNA2D1 | |
| SCHEMBL1768861 | 0.83 | CTSL (0.55) | TACR1CARM1PRMT6NAAASIGMAR1 | |
| SCHEMBL26221766 | 0.79 | CARM1 (0.61) | TACR1CARM1PRMT6NAAASLC6A4 | |
| SCHEMBL5998245 | 0.79 | TACR1 (0.58) | TACR1CARM1PRMT6SLC6A4IDO1 | |
| SCHEMBL72584 | 0.79 | SLC6A2 (0.50) | SLC6A4SLC6A9MGLLCACNA2D1CACNA1B | |
| SCHEMBL31381217 | 0.78 | MGLL (0.57) | CARM1PRMT6NAAAIDO1MGLL | |
| SCHEMBL12321049 | 0.77 | ACHE (0.45) | SLC6A4SLC6A9CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4635725 | 0.77 | NAAA (0.50) | TACR1CARM1PRMT6NAAACACNA2D1 | |
| SCHEMBL4636128 | 0.77 | SLC6A9 (0.50) | TACR1SLC6A4SLC6A9IDO1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617839-B1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RES LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | VERNALIS RESEARCH LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| CN-1780615-A | Use of azetidinecarboxamide derivatives in therapy | VERNALIS RES LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| EP-1617839-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096209-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1049672-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1212054-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-06-12 | — | — | EP | disclosed |
| US-6403574-B1 | TRANQUILIZERS, ANTIEPILEPTIC, MUSCLE RELAXATION PRIOR TO SURGERY | VERNALIS RESEARCH LIMITED (GB) | 2002-06-11 | — | — | US | disclosed |
| WO-2001007023-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049672-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037612-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | CNR1, CNR2, GPR18 | TACR1 76/4885CARM1 1976/4885PRMT6 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.